BioAtla (BCAB) announced preclinical poster presentations at the upcoming 2025 American Association for Cancer Research to be held at the McCormick Place Convention Center in Chicago, IL from April 25-30, 2025. Two abstracts accepted for poster presentation highlight Company’s proprietary Conditionally Active Biologic technology; Differentiated preclinical activity for CAB anti-Nectin4-antibody drug conjugate with superior efficacy to enfortumab vedotin analogue in lung, breast, pancreatic and urothelial patient derived cancer models; CAB technology provides a new generation of biologics with an increased safety margin and therapeutic index, selectively targeting acidic senescence and senescence-associated secretory phenotype cells in cancer and age-related diseases
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCAB:
- BioAtla price target lowered to $1 from $5 at Citizens JMP
- BioAtla’s Earnings Call: Clinical Progress and Strategic Outlook
- Positive Outlook for BioAtla: Strategic Moves and Promising Developments Signal Potential Upside
- BioAtla price target lowered to $10 from $13 at BTIG
- BioAtla, Inc. Reports 2024 Financial Results and Clinical Progress